'COVID-19 vaccination and blood clotting' leafelt

Made:
2021 in unknown place
maker:
National Health Service
'COVID-19 vaccination and blood clotting' leafelt (leaflet) 'COVID-19 vaccination and blood clotting' leafelt (leaflet) 'COVID-19 vaccination and blood clotting' leafelt (leaflet) 'COVID-19 vaccination and blood clotting' leafelt (leaflet)

Creative Commons LicenseThis image is released under a CC-BY-NC-SA 4.0 Licence

Buy this image as a print 

Buy

License this image for commercial use at Science and Society Picture Library

License

Creative Commons LicenseThis image is released under a CC-BY-NC-SA 4.0 Licence

Buy this image as a print 

Buy

License this image for commercial use at Science and Society Picture Library

License

Creative Commons LicenseThis image is released under a CC-BY-NC-SA 4.0 Licence

Buy this image as a print 

Buy

License this image for commercial use at Science and Society Picture Library

License

Creative Commons LicenseThis image is released under a CC-BY-NC-SA 4.0 Licence

Buy this image as a print 

Buy

License this image for commercial use at Science and Society Picture Library

License

Science Museum Group
© The Board of Trustees of the Science Museum

Science Museum Group
© The Board of Trustees of the Science Museum

Science Museum Group
© The Board of Trustees of the Science Museum

Science Museum Group
© The Board of Trustees of the Science Museum

A4 leaflet, 'COVID-19 vaccination and blood clotting', Public Health England and NHS, product code COV2021700 V2, 2021

At the time this leaflet was published over 34 million people had a COVID-19 vaccination. However, after 7 April 2021, advice about which vaccine to have changed. At this time, three vaccines were approved for use. The double-sided guide gives information about the elevated, yet extremely rare, risk of developing blood clotting problems following the Oxford AstraZeneca vaccine. Following guidance from the Joint Committee on Vaccination and Immunisation, this leaflet details which vaccine a person should be offered depending on their age and underlying health conditions. Anyone over 40 was offered any of the approved vaccines. Anyone under the age of 39 was offered alternatives to the Oxford Astra Zeneca vaccine. For those who already had one dose of the Oxford AstraZeneca vaccine with no adverse effects were advised to have their second dose.

Details

Category:
Public Health & Hygiene
Object Number:
2024-71
Materials:
paper
Measurements:
overall: 297 mm x 210 mm
type:
leaflet